Compare Johnson & Johnson (JNJ) vs Centrus Energy Corp (LEU) Price & Performance

Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.

JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.

Centrus Energy (LEU) trades at $156.39, showing modest daily gains amid a bearish technical signal. The company reported mixed quarterly earnings, with a recent beat in Q1 2026 but misses in prior quarters. Recent positive developments include a $1 billion Department of Energy contract and inclusion in the S&P SmallCap 600 index, highlighting its strategic role in the nuclear fuel supply chain. Valuation ratios appear elevated with a P/E of 56.87, while profitability metrics like a 13.4% net income margin indicate solid operational performance.

The outlook for LEU is cautiously optimistic, driven by government contracts and nuclear industry tailwinds, but high valuation and earnings volatility pose risks. Analyst consensus leans bullish with a $223.14 price target, though technical indicators suggest near-term pressure. Investors should weigh growth potential against execution risks and market sentiment shifts.